What does a C‑peptide level of 2.3 ng/mL indicate about endogenous insulin production and the likely type of diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

C-Peptide 2.3 ng/mL Interpretation

A C-peptide level of 2.3 ng/mL indicates preserved endogenous insulin production and strongly suggests type 2 diabetes or monogenic diabetes (MODY), effectively ruling out type 1 diabetes.

Clinical Significance

This value of 2.3 ng/mL (approximately 767 pmol/L) is well above the critical threshold of 1.8 ng/mL (600 pmol/L) that distinguishes preserved beta-cell function from severe insulin deficiency 1. According to the 2025 ADA Standards of Care, any C-peptide result >1.8 ng/mL indicates substantial endogenous insulin production regardless of testing circumstances 1.

Diabetes Classification Based on This Result

Type 1 Diabetes: Excluded

  • Type 1 diabetes typically shows C-peptide <0.6 ng/mL (200 pmol/L) 1
  • Values <0.2 nmol/L (0.6 ng/mL) are specifically associated with type 1 diabetes diagnosis 2
  • Your patient's level of 2.3 ng/mL is nearly 4 times higher than the upper limit for type 1 diabetes

Type 2 Diabetes: Most Likely

  • C-peptide levels >1.8 ng/mL strongly indicate type 2 diabetes 1
  • This preserved insulin production explains why patients can often be managed without insulin initially
  • Look for supporting features: BMI ≥25 kg/m², absence of weight loss, no ketoacidosis history, gradual symptom onset, features of metabolic syndrome 1

Monogenic Diabetes (MODY): Consider If:

  • Age <35 years at diagnosis
  • One parent with diabetes
  • BMI <25 kg/m²
  • Absence of autoimmune markers
  • MODY calculator probability >5% 1

Clinical Implications

This patient does not have absolute insulin deficiency and should not be managed with type 1 diabetes treatment strategies 3. The preserved beta-cell function indicated by this C-peptide level means:

  • Non-insulin therapies (metformin, GLP-1 agonists, SGLT2 inhibitors) are appropriate first-line options
  • If currently on insulin, consider de-escalation or transition to oral agents
  • Lower risk of diabetic ketoacidosis compared to insulin-deficient states 4
  • Better glycemic control potential with insulin-sensitizing medications

Important Caveats

Timing matters for interpretation: This C-peptide should have been measured within 5 hours of eating or with concurrent glucose >70 mg/dL to be valid 1. If measured during fasting or hypoglycemia, the result may be falsely low (though 2.3 ng/mL is high enough that this is unlikely to change interpretation).

Do not measure C-peptide within 2 weeks of diabetic ketoacidosis, as results will be artificially suppressed 1.

The intermediate range of 0.6-1.8 ng/mL can be ambiguous and may represent type 1 diabetes, MODY, or long-standing type 2 diabetes in lean individuals 1, but your patient's value of 2.3 ng/mL is clearly above this gray zone.

References

2
Research

A Practical Review of C-Peptide Testing in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017

3
Research

The clinical utility of C-peptide measurement in the care of patients with diabetes.

Diabetic medicine : a journal of the British Diabetic Association, 2013

Related Questions

What is the clinical purpose of measuring insulin and C‑peptide levels?
In a patient with a fasting C‑peptide within the reference interval but inappropriately low relative to the fasting glucose, what does this indicate and what further evaluation and management steps are recommended?
When should a C‑peptide test be ordered in adults and how are fasting and stimulated C‑peptide results interpreted for diabetes type differentiation, hypoglycemia evaluation, and assessment of residual β‑cell function?
When is a C‑peptide assay indicated for diabetes testing, and how should the sample be collected and interpreted?
How should C‑peptide be measured and interpreted in a patient receiving exogenous insulin therapy?
In a child younger than 25 years with severe hyperglycemia (HbA1c 10.9%), negative pancreatic islet autoantibodies, and a family history of diabetes in both parents, how should we assess for monogenic diabetes (Maturity‑Onset Diabetes of the Young, MODY), including recommended laboratory evaluation, genetic testing panel, and genotype‑specific treatment strategies?
In a man with benign prostatic hyperplasia and chronic kidney disease, which alpha‑blocker is preferred and what is the appropriate dosing regimen?
In a patient with a fasting C‑peptide within the reference interval but inappropriately low relative to the fasting glucose, what does this indicate and what further evaluation and management steps are recommended?
What are the indications, dosing regimens, and contraindications for tenecteplase in adult patients with acute ST‑segment‑elevation myocardial infarction (STEMI) or acute ischemic stroke?
Can gluten intolerance cause post‑prandial dyspnea, and how should I differentiate an allergic reaction from gastrointestinal or cardiopulmonary causes?
What is the recommended treatment algorithm for managing ketosis‑prone diabetes, including initial insulin therapy, assessment of beta‑cell function, and transition to oral antidiabetic agents?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.